Can High-Risk Myeloma Patients Become Refractory to Certain Monoclonal Antibodies?

Can High-Risk Myeloma Patients Become Refractory to Certain Monoclonal Antibodies?

Patient Power Community member, Francis, asks “Can refractory, high-risk myeloma patients become refractory to daratumumab?” Dr. Jatin Shah from the University of Texas MD Anderson Cancer Center responds to this question and goes on to discuss promising treatment options in clinical trials, specifically related to immunotherapy and checkpoint inhibitors.

patientpower.info/video/can...

oldestnewest

You may also like...